Clarinase Use In Pregnancy & Lactation

Pregnancy: Neither loratadine nor the combination of loratadine and pseudoephedrine were teratogenic in animal studies. The safe use of Clarinase Repetabs and Clarinase Extended-Release Tablets during pregnancy has not been established; however experience from a large number of exposed pregnancies in humans does not reveal any increase in the frequency of malformations as compared to the incidence in the general population.
Because animal reproduction studies are not always predictive of human response, and due to the vasoconstrictive properties of pseudoephedrine, Clarinase Repetabs and Clarinase Extended-Release Tablets should not be used during pregnancy.
Breast-feeding: Physico-chemical data suggest excretion of loratadine and pseudoephedrine/metabolites in human milk. Decreased milk production in nursing mothers has been reported with pseudoephedrine. A risk to the newborns/infants cannot be excluded. Therefore Clarinase Repetabs and Clarinase Extended-Release Tablets should not be used during breast-feeding.
Fertility: There are no data available on male and female fertility.